List of Excipients in Branded Drug RENAGEL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Atlantic Biologicals Corps	RENAGEL	renagel	17856-0021	FERROSOFERRIC OXIDE
Atlantic Biologicals Corps	RENAGEL	renagel	17856-0021	HYPROMELLOSE 2910
Atlantic Biologicals Corps	RENAGEL	renagel	17856-0021	ISOPROPYL ALCOHOL
Atlantic Biologicals Corps	RENAGEL	renagel	17856-0021	PROPYLENE GLYCOL
Atlantic Biologicals Corps	RENAGEL	renagel	17856-0021	SILICON DIOXIDE
Atlantic Biologicals Corps	RENAGEL	renagel	17856-0021	STEARIC ACID

Renagel Excipient Strategy and Commercial Opportunities in Sevelamer Hydrochloride

Last updated: August 6, 2026

Renagel is the original branded sevelamer hydrochloride phosphate binder. Its commercial opportunity has shifted from molecule ownership to formulation engineering, manufacturing efficiency, patient usability, and differentiated generic or authorized-generic products. The strongest opportunities are lower-pill-burden presentations, palatable powders, improved suspension behavior, and robust control of polymer attributes that affect phosphate binding and batch consistency.

Sevelamer is a nonabsorbed, crosslinked polymer containing amine groups. It binds dietary phosphate in the gastrointestinal tract and is used to control serum phosphorus in patients with chronic kidney disease on dialysis. Because the active ingredient is a polymer rather than a conventional soluble small molecule, excipient selection affects manufacturability, dose delivery, suspension performance, swallowing, stability, and potentially in vitro comparability.

What is Renagel and how does its formulation work?

Renagel contains sevelamer hydrochloride and was approved by the U.S. Food and Drug Administration for control of serum phosphorus in patients with chronic kidney disease on dialysis.[1] Sevelamer hydrochloride is a crosslinked polyallylamine polymer supplied in tablet form. The polymer is not systemically absorbed and acts locally in the gastrointestinal tract.

The formulation has four commercial constraints:

1. Sevelamer has a high dose requirement.
2. Tablets can create a substantial swallowing burden.
3. The polymer must remain chemically and physically stable during manufacturing and storage.
4. Product performance depends on polymer properties, particle size, crosslinking, hydration, and phosphate-binding capacity.

Renagel is closely related to Renvela, which contains sevelamer carbonate. Sevelamer carbonate was developed partly to avoid the chloride load associated with sevelamer hydrochloride and to provide tablet and powder dosage forms.[2]

How does sevelamer bind phosphate?

Sevelamer contains protonated amine groups that bind negatively charged phosphate in the gastrointestinal tract. The binding mechanism is ion exchange and electrostatic interaction. The polymer does not need to dissolve fully to perform its function, which distinguishes it from conventional immediate-release drugs.

This creates a formulation advantage and a regulatory challenge. Conventional dissolution testing may not fully describe product performance. Relevant quality attributes can include:

• Phosphate-binding capacity
• Binding kinetics at relevant pH values
• Polymer particle-size distribution
• Crosslink density
• Water content
• Swelling behavior
• Bulk density
• Tablet hardness and friability
• Disintegration or dispersion
• Suspension uniformity for powders
• Microbial quality for aqueous preparations after reconstitution

Which excipients are strategically important in Renagel-type products?

Excipient strategy should support processing and administration without reducing access to polymer amine sites or changing the product's binding behavior. The most important excipient categories are binders, lubricants, glidants, film-forming agents, wetting agents, suspending agents, and taste-masking materials.

Excipient function	Commercial purpose	Main technical risk
Binder	Provides tablet strength at high polymer loading	Slower dispersion or reduced binding accessibility
Lubricant	Prevents sticking and improves ejection	Hydrophobic coating and slower wetting
Glidant	Improves powder flow and die filling	Segregation or variable content uniformity
Film former	Improves handling and swallowability	Delayed hydration or altered disintegration
Wetting agent	Improves powder dispersion	Foam, compatibility, or taste effects
Suspending agent	Maintains uniformity in oral suspensions	Increased viscosity and dose-measurement problems
Sweetener or flavor	Improves powder acceptability	Stability, renal-diet compatibility, and sensory masking
Anticaking agent	Improves powder flow and reconstitution	Adsorption or altered dispersion

Why are lubricants important?

High-load polymer tablets often require lubrication to prevent sticking during compression. Excessive or poorly selected lubricant can create a hydrophobic surface that slows wetting and dispersion. For sevelamer, that may affect the rate at which the polymer becomes accessible to phosphate.

The commercial objective is not maximum tablet hardness. It is a balanced tablet with adequate mechanical strength, reliable disintegration, low friability, and rapid exposure of binding sites.

Why are binders difficult in high-dose polymer tablets?

A binder improves tablet integrity, but it can also increase tablet size and create a dense matrix that slows hydration. A highly compact tablet may be easier to package but harder for a patient to swallow and slower to disperse in the gastrointestinal tract.

Direct compression is commercially attractive because it reduces processing steps. Wet granulation may improve flow and content uniformity but can add water exposure, drying requirements, and variability in polymer hydration. Dry granulation can provide a compromise, although roller compaction may change particle morphology and compressibility.

What formulations are protected or commercially differentiated in Renagel products?

The main formulation platforms are tablets, oral powders, and suspension-oriented products. Each has a different commercial profile.

Tablet formulations

Tablets provide dose accuracy, packaging efficiency, and established patient familiarity. Their disadvantages are size and pill burden. Product developers can pursue:

• Higher-strength tablets
• Smaller tablets at equivalent dose
• Improved compression efficiency
• Low-friability tablets with faster wetting
• Film coatings that improve handling without blocking hydration
• Calendar or unit-dose packaging
• Tablet designs that reduce chipping and powdering

The central technical issue is maintaining phosphate-binding performance while reducing tablet volume.

Powder formulations

Powder products can reduce swallowing difficulty and may allow flexible dosing. They require strong control of:

• Powder flow
• Dose uniformity
• Moisture uptake
• Reconstitution behavior
• Suspension uniformity
• Flavor and mouthfeel
• Sachet or bottle dispensing accuracy

Powder is a significant opportunity because sevelamer therapy requires repeated daily administration and many patients have difficulty swallowing large tablets. A powder that disperses quickly with low sedimentation and acceptable taste can compete even if the active ingredient is not differentiated.

Oral suspension opportunities

A ready-to-use suspension could improve convenience but creates higher manufacturing and stability requirements. The product would need a controlled particle-size distribution, antimicrobial strategy where appropriate, packaging that limits settling, and a dosing device that delivers a reproducible amount.

The main barrier is physical stability. Sevelamer is intended to remain available for phosphate binding, but a suspension that settles rapidly or forms hard sediment can produce underdosing and poor adherence.

How can excipients reduce Renagel pill burden?

Pill burden is the largest commercial weakness of sevelamer therapy. Renagel dosing is individualized according to serum phosphorus and response, and patients may take multiple tablets with meals. Excipient engineering cannot remove the active polymer mass required for phosphate binding, but it can improve the amount of active polymer delivered per unit volume.

The most relevant strategies are:

1. Increase tablet density without creating an excessively slow-dispersing matrix.
2. Use high-efficiency compression and optimize particle-size distribution.
3. Develop higher-strength tablets where regulatory specifications permit.
4. Offer powders for patients who cannot swallow tablets.
5. Improve suspension uniformity so patients can take a single measured dose.
6. Reduce tablet friability and coating defects that create dose loss.

Pill-burden reduction is commercially valuable because phosphate binders compete on adherence as much as on acquisition cost. The product that is easier to take with every meal can gain share even in a generic market.

What FDA regulatory pathway applies to generic Renagel?

Generic sevelamer products are generally developed through the abbreviated new drug application pathway, but they are more complex than conventional immediate-release tablets. The active ingredient is a nonabsorbed polymer, so bioequivalence cannot rely only on conventional plasma pharmacokinetics.

FDA product-specific guidance for sevelamer products has focused on comparative pharmaceutical quality and pharmacodynamic or in vitro approaches appropriate to a locally acting, nonabsorbed binder.[3] Developers must control the active polymer and demonstrate that the proposed product performs comparably to the reference product.

Important regulatory issues include:

• Polymer identity and composition
• Degree of crosslinking
• Residual monomer and process impurities
• Phosphate-binding capacity
• Binding kinetics
• Particle-size distribution
• Tablet disintegration and dispersion
• In vitro comparative performance
• Stability under moisture stress
• Manufacturing reproducibility

The excipient profile should be selected early in development because changing excipients can require new comparative performance work. A formulation that is inexpensive to manufacture but difficult to bridge against the reference product may have poor commercial value.

What is the Orange Book status of Renagel?

The FDA Orange Book identifies approved products, reference-listed drugs, patents, and regulatory exclusivities where applicable.[4] Renagel's core market protection has expired, and commercial competition is driven primarily by generic entry, formulation execution, supply reliability, and contracting.

The relevant regulatory distinction is between:

• Sevelamer hydrochloride products compared with Renagel
• Sevelamer carbonate products compared with Renvela
• Tablet products compared with powder products
• Approved generic products and authorized-generic arrangements
• Product-specific formulation patents and process patents

A developer must review the current Orange Book rather than rely on historical brand-era patent lists. Patent listings can change through expiration, delisting, litigation outcomes, or FDA administrative updates.

When did Renagel lose exclusivity and what generic entry risks exist?

Renagel's principal composition-of-matter and early formulation protection is historical. The main current risk is not basic molecule invalidity. It is the technical and commercial difficulty of producing a consistent sevelamer product at a low cost.

Generic entry risks include:

Risk	Effect on market entry
In vitro performance mismatch	FDA review delay or additional studies
Polymer batch variability	Failed comparability or commercial recalls
Poor tablet robustness	High manufacturing loss and complaints
Moisture sensitivity	Shorter shelf life or packaging cost
Large tablet size	Lower adherence and weak substitution
Weak powder taste profile	Poor patient acceptance
Supply concentration	Vulnerability to shortages
Contracting pressure	Low net price despite approval

The highest-value generic opportunity is a product that combines regulatory comparability with a lower total cost of goods. A modest excipient change can create meaningful value if it improves compression yield, reduces coating steps, shortens processing time, or enables lower-cost packaging.

Which companies are challenging or competing with Renagel?

Competition comes from three groups:

1. Generic manufacturers of sevelamer hydrochloride.
2. Manufacturers of sevelamer carbonate products.
3. Alternative phosphate-binder manufacturers, including calcium-based binders, lanthanum carbonate, ferric citrate, and sucroferric oxyhydroxide.

Sevelamer carbonate competes directly with sevelamer hydrochloride because it uses the same polymer class and targets the same dialysis population. The carbonate product can be positioned around chloride exposure and broader dosage-form options.

Alternative binders compete on pill burden, price, gastrointestinal tolerability, mineral load, and dosing convenience. A sevelamer product with superior excipient-enabled administration can retain demand even after generic erosion.

What patent opportunities remain for Renagel-type formulations?

New opportunities are more likely to arise from narrow formulation and manufacturing claims than from broad claims covering sevelamer itself.

Potential patentable areas include:

• Specific excipient ratios that improve dispersion
• High-density tablet compositions
• Low-moisture manufacturing processes
• Particle-size distributions linked to binding performance
• Powder formulations with improved suspension stability
• Taste-masked powders
• Unit-dose sachets with moisture barriers
• Reconstitution systems
• Manufacturing controls for crosslink density
• Process conditions that reduce residual impurities
• Combination products with meal-specific dosing systems

Method-of-use patents may cover administration to particular patient populations, dosing schedules, or use with specific dietary or dialysis conditions. Their commercial value is usually narrower than a composition patent and can be difficult to enforce where generic labels omit the patented indication.

A formulation patent is strongest when the claimed excipient system produces a measurable technical effect, such as improved phosphate-binding kinetics, reduced tablet size, longer stability, or superior suspension uniformity. A claim based only on routine excipient substitution is more vulnerable to obviousness challenges.

How does Renagel compare with Renvela?

Attribute	Renagel	Renvela
Active ingredient	Sevelamer hydrochloride	Sevelamer carbonate
Primary dosage forms	Tablets	Tablets and oral powder options
Chloride exposure	Present as hydrochloride salt	Reduced chloride contribution
Core commercial role	Original sevelamer product	Later-generation sevelamer product
Main formulation opportunity	Smaller, stronger tablets	Powder, suspension, and convenience improvements
Competitive pressure	Generic sevelamer hydrochloride	Generic sevelamer carbonate and alternatives

Renvela provides the more attractive platform for powder and suspension innovation. Renagel-type products remain relevant where hydrochloride products have established substitution, reimbursement, or supply advantages.

What licensing and commercial deals are relevant?

The primary licensing opportunity is no longer broad access to sevelamer chemistry. It is access to differentiated delivery technology, manufacturing know-how, or regional commercialization rights.

Potential deal structures include:

• Regional rights for generic sevelamer tablets
• Authorized-generic supply agreements
• Contract manufacturing of high-load polymer tablets
• Licensing of taste-masked powder technology
• Co-development of reconstitutable suspensions
• Technology transfer for moisture-resistant packaging
• Distribution agreements in dialysis-focused markets
• Supply agreements with dialysis providers and group purchasing organizations

A licensee should value the product according to net realized price, not list price. Generic phosphate binders face substantial payer and dialysis-provider negotiating pressure. Manufacturing scale, dependable supply, and low complaint rates can matter more than incremental formulation differentiation.

What is the commercial opportunity for excipient suppliers?

Excipient suppliers can capture value by providing functional materials with documented performance in high-dose, nonabsorbed polymer systems. The most attractive offerings are not generic commodity excipients alone. They are excipient systems supported by process data.

Commercially relevant product attributes include:

• Low-moisture grades
• Consistent particle-size distributions
• Improved flow and compressibility
• Low lubricant demand
• Fast wetting
• Low foaming in powder suspensions
• Taste-masking capability
• Compatibility with high polymer loading
• Regulatory documentation for global markets

A supplier that can show lower compression force, reduced sticking, faster disintegration, or improved suspension uniformity has a stronger negotiating position than one offering only a nominally equivalent grade.

What generic launch scenarios should investors consider?

Three launch scenarios are commercially realistic.

Low-cost tablet substitution

The product matches the reference product closely and competes primarily on price. This is the fastest route to volume but offers limited margin protection.

Convenience-led powder entry

The product uses a powder format with better dispersion or taste. It may command a higher net price and target patients with swallowing difficulty, but development and commercial education costs are higher.

Integrated formulation and supply platform

The company offers tablets, powder, and dependable supply to dialysis channels. This approach requires greater investment but creates stronger contracting leverage and reduces dependence on a single dosage form.

The strongest product profile combines a low-cost tablet for broad substitution with a differentiated powder for adherence-sensitive patients.

Key Takeaways

• Renagel is the original sevelamer hydrochloride phosphate binder; the active polymer is nonabsorbed and locally active.
• The principal commercial opportunity is formulation execution rather than broad molecule protection.
• Excipients must improve manufacturability and administration without reducing phosphate-binding accessibility.
• High-value strategies include smaller high-strength tablets, low-moisture processing, palatable powders, and stable suspensions.
• Generic development requires control of polymer attributes, phosphate-binding performance, dispersion, and batch consistency.
• Renvela and alternative phosphate binders create direct competitive pressure.
• Formulation and manufacturing patents are more commercially relevant than expired foundational sevelamer claims.
• Excipient suppliers can differentiate through validated performance in high-polymer-load systems.
• The best launch strategy combines cost-efficient tablets with a convenience-oriented powder or suspension.

FAQs

Is Renagel still commercially relevant after generic entry?

Yes. Sevelamer hydrochloride remains relevant in dialysis markets where prescribers, payers, and providers are familiar with the product class. Its commercial position depends on price, supply, dosage-form usability, and contracting.

Can an excipient change create a patentable sevelamer product?

It can, if the excipient combination produces a demonstrated technical effect and the claims satisfy novelty, nonobviousness, written-description, and enablement requirements. Routine substitution of standard tablet excipients is less defensible.

Does Renagel require a biosimilar pathway?

No. Sevelamer is a synthetic, nonabsorbed polymer and is not regulated as a biologic. Generic products generally use an ANDA-based pathway, subject to product-specific comparative-performance requirements.

Which dosage form offers the largest commercial opportunity?

Powder is the most promising differentiated dosage form because it can address swallowing difficulty and dosing flexibility. Tablets remain the largest opportunity for low-cost substitution and broad payer coverage.

What is the most important manufacturing barrier for sevelamer products?

The primary barrier is consistent control of polymer and tablet performance at high active loading. Flow, compression, moisture, dispersion, and phosphate-binding variability can determine whether an approved formulation is commercially viable.

References

1. U.S. Food and Drug Administration. (1998). Renagel (sevelamer hydrochloride) prescribing information. FDA.

2. U.S. Food and Drug Administration. (2007). Renvela (sevelamer carbonate) prescribing information. FDA.

3. U.S. Food and Drug Administration. (2024). Product-specific guidance for sevelamer hydrochloride and sevelamer carbonate oral dosage forms. FDA.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

5. Chertow, G. M., Burke, S. K., Raggi, P., & Treat to Goal Working Group. (2002). Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney International, 62(1), 245-252.

6. National Library of Medicine. (2024). Renagel: Sevelamer hydrochloride drug label. DailyMed.